PATENT CLAIM ANALYSIS

Application Number: 16146980
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-04
Patent Classification: ["435", "455000"]

Abstract:
Described herein are human transgenic beta cells expressing fugetactic levels of CXCL12 to a subject in need thereof. Also described herein are beta cells comprising a transgene comprising a nucleic acid sequence encoding CXCL12.

Claim (Index 5):
The human beta cell of  claim 2 , wherein said human immune cells comprise NK cells, cytotoxic T cells and/or B cells.

Metadata:
- Claim Count in Document: 44.0
- Percentile: 97.0
- Lexical Diversity: 1.33333
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['11667410', '15840930', '15258887', '15179567', '15590587']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5785258973717646
- 35 USC 102 Novelty (BERT): 0.497712258145606
- Combined Prediction Score: 0.5704445334491488
- Mean Citation Score: 192.89315
- Max Citation Score: 198.78343
- Similarity Product: 124.47959786541225

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test